Cardiac-Safe Agitation Medications
For patients with cardiac disease or QT prolongation risk, aripiprazole is the safest first-line antipsychotic for agitation, followed by olanzapine, while benzodiazepines and valproate serve as non-antipsychotic alternatives when QTc exceeds 500 ms. 1
Risk-Stratified Medication Selection
Patients with Risk Factors but Normal QTc (<500 ms)
First-line options:
- Aripiprazole (oral or IM): No QT prolongation demonstrated in meta-analyses 2, 3
- Olanzapine (oral or IM): Low-quality evidence shows no QT increase 2
- Benzodiazepines: No cardiac ion channel effects 4
Second-line options:
- Risperidone: Similar cardiac safety profile to olanzapine 5
- Quetiapine: Associated with 30% lower risk of sudden cardiac death/ventricular arrhythmia compared to olanzapine 5
Patients with QTc 500-520 ms
Restrict to:
- Aripiprazole (preferred)
- Olanzapine
- Risperidone
- Quetiapine
- Valproate (non-antipsychotic mood stabilizer) 1
Patients with QTc >500 ms or Multiple Risk Factors
Use only:
- Aripiprazole (safest antipsychotic option)
- Valproate
- Trazodone
- Benzodiazepines 1
Medications to Avoid in Cardiac Patients
High-risk antipsychotics (Class B* - documented TdP risk):
- Ziprasidone: Highest risk (HR 1.72) with documented QTc prolongation 6, 2
- Haloperidol: 2.68-fold increased risk of sudden cardiac death, dose-dependent 5
- Chlorpromazine: 2.54-fold increased risk 5
- Amisulpride: HR 1.56 for QTc prolongation 6
The guideline emphasizes that antipsychotics and antidepressants are among the most common culprits for drug-induced QT prolongation, falling under the "anti's" to remember (antibiotics, antifungals, antiarrhythmics, antipsychotics/antidepressants, antiemetics) 7.
Critical Monitoring Requirements
Before initiating any antipsychotic in cardiac patients:
- Obtain baseline ECG if patient has electrolyte disturbances, is already on QT-prolonging drugs, or you're starting a high-risk agent 7
- Check potassium, magnesium, calcium levels
- Review all concurrent medications at www.crediblemeds.org 7
Risk increases significantly when:
- QTc exceeds 500 ms or increases by >60-70 ms rapidly 7
- Female sex, age >65, structural heart disease present 7
- Multiple QT-prolonging drugs combined
- Diuretics causing electrolyte depletion 7
Important Clinical Nuances
Within-class differences matter: Among antipsychotics, the cardiac risk does not correlate well with average QT prolongation 5. Real-world sudden cardiac death data shows haloperidol and chlorpromazine have worse outcomes than their QT effects would predict, while quetiapine performs better than expected.
Common pitfall: Switching to metoprolol or atenolol for beta-blockade in LQTS patients is inferior to nadolol/propranolol 7. This is relevant because agitated cardiac patients may already be on beta-blockers.
Avoid these drugs for TdP/arrhythmic storm: Never use amiodarone or procainamide in patients with prolonged QT and arrhythmias—they worsen QT prolongation 7. Use beta-blockade, magnesium, and lidocaine instead.
Practical Algorithm
- Check baseline QTc and electrolytes
- If QTc <500 ms: Use aripiprazole or olanzapine IM/PO
- If QTc 500-520 ms: Limit to aripiprazole, olanzapine, or benzodiazepines
- If QTc >520 ms: Use only benzodiazepines, valproate, or trazodone; consider aripiprazole only with cardiology consultation
- Monitor ECG after dose changes if using any antipsychotic in at-risk patients 7
The 2023 Canadian Cardiovascular Society guidelines emphasize that women are at higher risk for acquired LQTS from medications, requiring extra vigilance 7.